tradingkey.logo

Lilly signs up to $1.3 billion deal with Superluminal Medicines to develop obesity medicines

ReutersAug 14, 2025 12:11 PM

- Eli Lilly LLY.N has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs targeting cardiometabolic diseases and obesity, Superluminal said on Thursday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI